share_log

Impulse (Qingdao) Health Tech Co.,Ltd.'s (SZSE:002899) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥518m Last Week

Impulse (Qingdao) Health Tech Co.,Ltd.'s (SZSE:002899) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥518m Last Week

Impulse(青島)健康科技有限公司, Ltd. 's(SZSE:002899)最大股東是個人投資者,上週市值飆升5.18億元人民幣,他們獲得了回報
Simply Wall St ·  04/25 21:00

Key Insights

關鍵見解

  • The considerable ownership by individual investors in Impulse (Qingdao) Health TechLtd indicates that they collectively have a greater say in management and business strategy
  • The top 25 shareholders own 45% of the company
  • Past performance of a company along with ownership data serve to give a strong idea about prospects for a business
  • 個人投資者擁有Impulse(青島)健康科技有限公司的大量所有權,這表明他們在管理和業務戰略方面集體擁有更大的發言權
  • 前25名股東擁有公司45%的股份
  • 公司過去的表現以及所有權數據可以使人們對企業前景有一個很好的了解

A look at the shareholders of Impulse (Qingdao) Health Tech Co.,Ltd. (SZSE:002899) can tell us which group is most powerful. The group holding the most number of shares in the company, around 45% to be precise, is individual investors. Put another way, the group faces the maximum upside potential (or downside risk).

看看Impulse(青島)健康科技有限公司的股東, Ltd.(深圳證券交易所:002899)可以告訴我們哪個集團最強大。持有公司股份最多的集團是個人投資者,準確地說約爲45%。換句話說,該集團面臨最大的上行潛力(或下行風險)。

As a result, individual investors were the biggest beneficiaries of last week's 3.8% gain.

因此,個人投資者是上週3.8%漲幅的最大受益者。

In the chart below, we zoom in on the different ownership groups of Impulse (Qingdao) Health TechLtd.

在下圖中,我們放大了Impulse(青島)健康科技有限公司的不同所有權組。

ownership-breakdown
SZSE:002899 Ownership Breakdown April 26th 2024
SZSE: 002899 所有權明細 2024 年 4 月 26 日

What Does The Institutional Ownership Tell Us About Impulse (Qingdao) Health TechLtd?

關於Impulse(青島)健康科技有限公司的機構所有權告訴我們什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。

We can see that Impulse (Qingdao) Health TechLtd does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Impulse (Qingdao) Health TechLtd's historic earnings and revenue below, but keep in mind there's always more to the story.

我們可以看到,Impulse(青島)健康科技有限公司確實有機構投資者;他們持有該公司很大一部分股票。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到Impulse(青島)健康科技有限公司的歷史收益和收入,但請記住,故事總是有更多內容。

earnings-and-revenue-growth
SZSE:002899 Earnings and Revenue Growth April 26th 2024
SZSE: 002899 2024年4月26日收益和收入增長

Hedge funds don't have many shares in Impulse (Qingdao) Health TechLtd. Looking at our data, we can see that the largest shareholder is Hainan Jiangheng Industrial Investment Co., Ltd. with 34% of shares outstanding. Yeah Fortune China Investment Limited is the second largest shareholder owning 2.4% of common stock, and Shanghai Deyi Investment Management Co., Ltd. holds about 1.9% of the company stock.

對沖基金在Impulse(青島)健康科技有限公司的股份不多。從我們的數據來看,我們可以看到最大股東是海南江恒實業投資有限公司,已發行股份的34%。是的,財富中國投資有限公司是第二大股東,擁有2.4%的普通股,上海德易投資管理有限公司持有該公司約1.9%的股份。

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

在研究我們的所有權數據時,我們發現25位大股東共同擁有的股份不到50%,這意味着沒有一個人擁有多數股權。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。我們的信息表明,分析師對該股沒有任何報道,因此可能鮮爲人知。

Insider Ownership Of Impulse (Qingdao) Health TechLtd

Impulse(青島)健康科技有限公司的內部所有權

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。公司管理層經營業務,但首席執行官將對董事會負責,即使他或她是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our data cannot confirm that board members are holding shares personally. Not all jurisdictions have the same rules around disclosing insider ownership, and it is possible we have missed something, here. So you can click here learn more about the CEO.

我們的數據無法證實董事會成員親自持有股份。並非所有司法管轄區在披露內部所有權方面都有相同的規則,我們有可能在這裏遺漏了一些東西。因此,您可以單擊此處了解有關首席執行官的更多信息。

General Public Ownership

一般公有制

With a 45% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Impulse (Qingdao) Health TechLtd. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Impulse(青島)健康科技有限公司擁有45%的所有權,主要是個人投資者,對Impulse(青島)健康科技有限公司有一定程度的影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 30%, of the Impulse (Qingdao) Health TechLtd stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

私人公司似乎擁有Impulse(青島)健康科技有限公司30%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Impulse (Qingdao) Health TechLtd you should know about.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,考慮風險。每家公司都有它們,我們發現了一個你應該知道的Impulse(青島)健康科技有限公司的警告標誌。

Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.

當然,這可能不是最值得買入的股票。因此,您可能希望看到我們免費收集的具有良好財務狀況的有趣潛在客戶。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論